These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9726092)

  • 21. Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
    Goldberg RM; Erlichman C
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):59-63. PubMed ID: 9726093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.
    Shimada Y; Rougier P; Pitot H
    Eur J Cancer; 1996; 32A Suppl 3():S13-7. PubMed ID: 8943660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
    Kramar A; Gourgou-Bourgade S; Ychou M
    J Clin Oncol; 2005 Jan; 23(3):650; author reply 650-1. PubMed ID: 15659517
    [No Abstract]   [Full Text] [Related]  

  • 24. Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer.
    Oostendorp LJ; Stalmeier PF; Pasker-de Jong PC; Van der Graaf WT; Ottevanger PB
    Anticancer Drugs; 2010 Sep; 21(8):749-58. PubMed ID: 20616701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irinotecan (Campto) in the treatment of pancreatic cancer.
    Pizzolato JF; Saltz LB
    Expert Rev Anticancer Ther; 2003 Oct; 3(5):587-93. PubMed ID: 14599083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irinotecan: a new antineoplastic agent for the management of colorectal cancer.
    Cersosimo RJ
    Ann Pharmacother; 1998 Dec; 32(12):1324-33. PubMed ID: 9876815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
    Rougier P; Van Cutsem E; Bajetta E; Niederle N; Possinger K; Labianca R; Navarro M; Morant R; Bleiberg H; Wils J; Awad L; Herait P; Jacques C
    Lancet; 1998 Oct; 352(9138):1407-12. PubMed ID: 9807986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [CPT-11: new drug for metastatic colorectal cancer].
    Barone C; Pozzo C; Cassano A
    Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
    Rothenberg ML
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
    Rougier P; Bugat R
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
    Cunningham D
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):1-5. PubMed ID: 10213008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
    Prescrire Int; 2005 Dec; 14(80):215-7. PubMed ID: 16400742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irinotecan may extend survival in people with metastatic colorectal cancer.
    Oncology (Williston Park); 1998 Oct; 12(10):1512. PubMed ID: 9798204
    [No Abstract]   [Full Text] [Related]  

  • 35. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A risk-benefit assessment of irinotecan in solid tumours.
    Siu LL; Rowinsky EK
    Drug Saf; 1998 Jun; 18(6):395-417. PubMed ID: 9638386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Irinotecan in combination for colon cancer].
    Ducreux M; Gil-Delgado M; André T; Ychou M; de Gramond A; Khayat D
    Bull Cancer; 1998 Dec; Spec No():43-6. PubMed ID: 9932084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
    Mitry E; Douillard JY; Van Cutsem E; Cunningham D; Magherini E; Mery-Mignard D; Awad L; Rougier P
    Ann Oncol; 2004 Jul; 15(7):1013-7. PubMed ID: 15205193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
    Desai AA; Kindler HL; Taber D; Agamah E; Mani S; Wade-Oliver K; Ratain MJ; Vokes EE
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):421-6. PubMed ID: 15895230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Irinotecan and thalidomide in metastatic colorectal cancer.
    Govindarajan R
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):29-32. PubMed ID: 11204671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.